Clearly labeled analysis and opinion, kept separate from the news. Facts link to their sources; conclusions are ours.
October 25, 2026
Two trends in states without legal adult-use cannabis are usually reported separately. Taken together, they point one way: in these states, legal THC is shrinking in hemp shops and growing in state-licensed medical programs that only registered patients can use.
Texas shows both halves, through a 2025 medical law and 2026 regulatory and court actions on hemp. A 2025 law, HB 46, replaced the medical program's 1%-by-weight THC cap with a limit of 10 milligrams of THC per dose, added chronic pain and other conditions, and allowed vaping; state-approved vape devices went on sale in June 2026. Meanwhile, Texas health regulators began counting THCA toward total THC on March 31, 2026, a rule a court blocked for several weeks this spring and that is still being challenged, and listed delta-8 and other non-delta-9 THC isomers as Schedule I on July 31.
Georgia shows the medical side most clearly. A 2026 bill to restrict hemp, SB 33, was rewritten into a property-tax law before passage, so licensed retailers can still sell delta-8 and other hemp THC products to adults 21 and older under state law. Lawmakers did pass SB 220, which took effect July 1 and replaced the medical program's 5% THC cap with a 12,000-milligram possession limit. It also lets patients over 21 vaporize oil or flower in private.
Elsewhere, medical programs are opening or growing, while the hemp cutback comes mostly from the federal change and, in Nebraska, the attorney general's enforcement. Kentucky's program began sales in December 2025, had 26 dispensaries open by mid-October 2026, and recognized 15 more qualifying conditions, by emergency regulation on June 2 and permanently on Oct. 20. Alabama's first medical dispensaries opened between June and September 2026. Nebraska approved its program rules in July 2026, though no dispensaries are licensed yet.
The federal change scheduled for Dec. 11 sharpens the contrast. It redefines hemp, excluding hemp-derived products with more than 0.4 milligrams of total THC per container, a measure that counts THCA and similar cannabinoids. It does not govern state-licensed medical marijuana, which was never legal hemp.
The likely result is a smaller, more controlled market: fewer outlets, a doctor's recommendation required, and in several states more product forms for patients than before. If the federal cap takes effect as scheduled, adults without a qualifying condition will lose hemp products above it and gain no state-licensed alternative. The numbers worth watching next are patient enrollment and dispensary counts in each of these states.
Sources: State Law Tracker: Texas · State Law Tracker: Georgia · State Law Tracker: Kentucky · State Law Tracker: Alabama · State Law Tracker: Nebraska · Texas HB 46 (2025), enrolled text
October 25, 2026
On Dec. 11, 2026, hemp products with more than 0.4 milligrams of total THC per container are scheduled to fall outside the federal definition of hemp. Many THC seltzers carry 2 to 10 milligrams per can, and some carry more. Read alone, the rule sounds like the end of the category. The state laws passed this year describe a more complicated picture.
Several states have spent 2026 setting rules for who may sell THC drinks. Since Oct. 1, Connecticut, which already limited THC drinks to package stores and cannabis retailers, has raised the cap to 5 milligrams per container at package stores, up from 3, and 10 milligrams at cannabis retailers. Delaware's HB 373, in effect Oct. 21, lets licensed liquor and marijuana stores and authorized microbreweries sell delta-9 drinks of up to 10 milligrams per single-serving can, or 170 milligrams per 750-milliliter bottle. That law also ends those authorizations automatically when the federal change takes effect.
Other states are folding stronger drinks into their cannabis systems on a set date. New Jersey liquor stores may sell hemp drinks only until Nov. 13; after that, drinks over 0.4 milligrams per container are treated as cannabis. Illinois reclassifies intoxicating hemp as cannabis on Nov. 12. Missouri limits most intoxicating hemp sales to licensed marijuana businesses from the same date, though for drinks the restriction is tied to the federal change on Dec. 11; a hemp trade group is challenging the law in federal court. Minnesota, which licenses lower-dose hemp drinks, says the federal change does not alter their legality under state law.
The common thread is licensing. In these states, THC drinks are being limited to licensed sellers, either cannabis retailers or liquor stores with state permits. New Jersey, Illinois and Missouri go further and treat stronger drinks as cannabis, while Minnesota keeps its hemp-drink licenses and Delaware's drink law ends when the federal change takes effect. Outside federal hemp, a THC drink is federally a controlled substance even when a state licenses it, but states decide whether and where it can be sold.
States without such a market have no licensed cannabis counter to move them to. There, drinks above the cap are set to lose federal hemp status on Dec. 11 with nowhere licensed to go, even where state law, as in Alabama, licenses hemp drink sales; drinks at or under 0.4 milligrams per container remain legal hemp. Unless Congress changes the date again, the same federal rule will play out very differently depending on where a shopper lives.
Sources: State Law Tracker: Connecticut · State Law Tracker: Delaware · State Law Tracker: New Jersey · State Law Tracker: Illinois · State Law Tracker: Missouri · State Law Tracker: Minnesota · State Law Tracker: Alabama
March 21, 2026 · Updated October 25, 2026
When Texas began counting THCA toward total THC on March 31, 2026, the effect on hemp shelves was uneven. Smokable flower stopped passing the test. Gummies and drinks did not.
The reason is chemistry, not an exemption. Texas hemp products must stay at or below 0.3% THC by dry weight, counting both delta-9 THC and THCA. A gummy is mostly sugar and gelatin, so a 3.5-gram gummy can carry about 10 milligrams of THC and stay under the limit. Flower is different: under the total-THC formula (delta-9 plus 0.877 times THCA), flower with 25% THCA tests at roughly 22%, far above the cap.
That leaves a practical gap for regular users. A 25-milligram gummy would need to weigh more than 8 grams to stay compliant. Higher doses require heavier or multiple pieces, which raises the cost per dose. People who cannot use edibles, because of how slowly they act or how their bodies absorb them, lost their main option when smokable products came off the shelves.
Texas then went further. Since July 31, 2026, delta-8, THCP and other THC isomers have been Schedule I controlled substances in the state, and the THCA rule, which a court blocked for several weeks this spring, remains in force while the challenge continues.
A federal change comes next. A funding law signed in November 2025 narrows the legal definition of hemp, and a stopgap law signed Sept. 2, 2026, split its start into two dates: products containing cannabinoids that a cannabis plant cannot naturally produce fall outside the definition on Nov. 12, 2026, and the rest of the change, including the exclusion of chemically converted cannabinoids and a limit of 0.4 milligrams of total THC per container, takes effect Dec. 11, 2026. That limit is per container, not per serving, so a single standard gummy exceeds it many times over.
For Texas shoppers, the result is two layers of rules arriving in the same year. For anyone deciding what to buy, sell or stock, the dates matter more than the slogans: March 31 and July 31 in Texas, Nov. 12 and Dec. 11 nationally.
Sources: State Law Tracker: Texas · Congressional Research Service on the federal hemp redefinition
March 15, 2026 · Updated October 25, 2026
Professions change when the evidence changes. Switchboard operators, darkroom technicians and elevator operators did skilled work that later technology replaced. Nobody considers their careers wasted. The work fit the tools and knowledge of its time.
Federal cannabis policy deserves the same plain treatment. The Controlled Substances Act placed marijuana in Schedule I in 1970, pending the work of a national commission. In 1972 that commission, chaired by former Pennsylvania Gov. Raymond Shafer, recommended ending criminal penalties for possession for personal use. The recommendation was not adopted, and the classification stayed in place for more than five decades.
The people who enforced that policy were following the law as written. Revisiting the classification does not condemn their work. It reflects what has been learned since: the FDA has approved a cannabis-derived medicine for certain seizure disorders, a National Academies review found substantial evidence that cannabis is effective for chronic pain in adults, and most states now run medical programs.
The federal government has begun to move. In April 2026, the Justice Department ordered state-licensed medical marijuana moved to Schedule III, and that order is now being challenged in court.
Our view is simple. A classification should follow the evidence, and changing it when the evidence changes is how a functioning system is supposed to work. Doing so is not a concession. It is the job.
Sources: The Health Effects of Cannabis and Cannabinoids (National Academies, 2017) · FDA: Cannabis research and drug approval · Federal Register: April 28, 2026 rescheduling order
March 15, 2026 · Updated October 25, 2026
The 2018 Farm Bill legalized hemp and its derivatives, and within a few years hemp-derived THC products such as delta-8 and low-dose delta-9 gummies were sold in gas stations, smoke shops and online across most of the country, often without age limits, testing rules or standard labels.
That stretch produced a real public record. It does not show a wave of deaths from THC itself; federal health officials describe a fatal overdose from cannabis alone as unlikely. It does show problems that come from selling an intoxicant without rules: poison centers reported rising calls about delta-8 products, many involving children who ate products that looked like candy, and federal regulators warned about inaccurate labels and unregulated manufacturing.
Both parts of that record point the same way. The products did not need to disappear for the problems to be fixed. Age limits, child-resistant packaging, potency labels and contaminant testing address the documented harms directly, the same way those rules work for alcohol and tobacco.
Federal policy has taken a different course. The legal definition of hemp narrows on Nov. 12, 2026 for cannabinoids a cannabis plant cannot naturally produce, and on Dec. 11, 2026 for the rest, including chemically converted cannabinoids and products over 0.4 milligrams of total THC per container. Some states are moving intoxicating hemp into their licensed cannabis systems instead.
Our position is that rules should match the evidence: regulate what causes harm, test what is sold, and keep it away from children. Seven years of sales gave lawmakers the information to do exactly that.
Sources: FDA: 5 things to know about delta-8 THC · Congressional Research Service on the federal hemp redefinition · CDC: Cannabis FAQ
March 10, 2026 · Updated October 25, 2026
Many Texas veterans used hemp-derived THC products to manage pain, sleep and PTSD symptoms after the 2018 Farm Bill made those products legal. That access has narrowed in steps.
A Texas rule that counts THCA toward total THC took effect March 31, 2026; after a court blocked it from April to early June, an appeals court let it take effect again, and it remains in force while the challenge continues. It makes most smokable hemp flower noncompliant. Since July 31, 2026, delta-8, THCP and other THC isomers have been Schedule I controlled substances in the state. A federal limit of 0.4 milligrams of total THC per container takes effect Dec. 11, 2026.
The legal route that remains is the Texas Compassionate Use Program. PTSD has been a qualifying condition since 2021, and a 2025 law (HB 46) replaced the 1%-by-weight THC cap with a limit of 10 milligrams per dose, added chronic pain and traumatic brain injury, and allowed state-approved vape devices when a prescription authorizes inhalation. Patients need a registered physician's prescription and buy from licensed dispensing organizations.
That program is still small. Only the original three licensees were operating as of September 2026, smoking and flower are not allowed, and enrollment requires a doctor visit that hemp shoppers never needed.
Veterans who relied on hemp products have three practical questions: whether they qualify for the medical program, where the nearest licensed provider is, and what their current products contain. Our Texas page tracks the rules and their sources as they change.
Sources: State Law Tracker: Texas · Texas HB 46 (2025), enrolled text · Texas DPS: Compassionate Use Program
March 3, 2026 · Updated October 25, 2026
Public-health data draw a sharp line between cannabis and the most dangerous legal drugs. The CDC attributes more than 178,000 deaths a year in the United States to excessive alcohol use and more than 480,000 to cigarette smoking and secondhand smoke. Opioids were involved in about 54,000 overdose deaths in 2024, down from about 79,000 in 2023.
Cannabis does not fit that pattern. The CDC states that a fatal overdose caused solely by cannabis is unlikely. In 1988 a DEA administrative law judge, Francis Young, wrote that a smoker would theoretically have to consume nearly 1,500 pounds of marijuana within about 15 minutes to induce a lethal response.
Low overdose risk is not the same as no risk. The same federal sources describe real harms: impaired driving, cannabis use disorder, severe vomiting syndrome in some frequent users, and effects on the developing brain. Accidental ingestion by young children, often of edibles, has risen as products have spread.
These numbers are a guide to proportion. A drug policy built on evidence would weigh cannabis by its actual risks, set rules to prevent the harms that are documented, and treat alcohol and tobacco by the same standard.
Sources: CDC: Deaths from excessive alcohol use · CDC: Cannabis FAQ · CDC: Tobacco-related mortality · NCHS Data Brief 549: Drug overdose deaths in 2024
March 4, 2026 · Updated October 25, 2026
Hemp is an old crop with a broad set of uses. Its fiber goes into textiles, rope, paper and building materials such as hempcrete; its seed is pressed for oil or sold as food; and it grows with comparatively few inputs.
The 2018 Farm Bill made hemp federally legal again, defining it as cannabis with no more than 0.3% delta-9 THC. That definition opened the door for fiber and grain farmers. It also opened the door to intoxicating products made from hemp, which grew into a large consumer market of its own.
The federal rewrite now under way is aimed at that second group. Beginning Nov. 12, 2026, products containing cannabinoids that a cannabis plant cannot naturally produce fall outside the definition of hemp; on Dec. 11, 2026, so do products with chemically converted cannabinoids or more than 0.4 milligrams of total THC per container.
Fiber and grain producers are not the target, but they share the same definition and the same testing rules. How regulators apply the new definition will decide whether the industrial side of hemp keeps growing while the intoxicating side shrinks.
We will report each rule as it is written and each date as it arrives.
Sources: Congressional Research Service on the federal hemp redefinition · USDA: Hemp production
March 5, 2026 · Updated October 25, 2026
For decades, federal rules made cannabis hard to study. Researchers needed special registration, and for years could use only government-supplied cannabis. That left real gaps in what is known.
The strongest summary remains the National Academies review published in 2017, which considered more than 10,000 scientific abstracts. It found conclusive or substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults, for nausea and vomiting caused by chemotherapy, and for patient-reported muscle spasms in multiple sclerosis.
The same review found evidence of risks: an association between cannabis use and the development of schizophrenia and other psychoses, a higher risk of motor vehicle crashes, and lower birth weight when mothers smoke during pregnancy. The FDA has approved a cannabis-derived medicine, Epidiolex, for seizures linked to certain rare forms of epilepsy, along with synthetic THC drugs for nausea and appetite loss.
Barriers are easing. A 2022 federal law, the Medical Marijuana and Cannabidiol Research Expansion Act, simplified the approval process for researchers. Better studies should follow, and we will report what they find, including results that cut against popular claims.
Sources: The Health Effects of Cannabis and Cannabinoids (National Academies, 2017) · FDA: Cannabis research and drug approval
March 5, 2026 · Updated October 25, 2026
As of October 2026, adult-use cannabis is legal in 24 states, and our State Law Tracker counts 41 states with a legal medical cannabis program, though some are narrow and Nebraska's has no licensed dispensaries yet. Public support for legalization has held above 60% in Gallup's polling for most of the past decade.
Abroad, the picture is mixed. Canada legalized adult use nationally in 2018. Germany legalized possession, home growing and nonprofit cannabis clubs in 2024 but has no commercial retail market. Thailand decriminalized cannabis in 2022 and has since moved to restrict recreational use again.
Early results from U.S. states are measurable. Most studies of U.S. states that legalized adult use have found little or no increase in teen use, though some reviews report increases on certain measures. Colorado has collected more than $3.2 billion in marijuana tax and fee revenue since sales began in 2014.
Some questions remain open, including effects on impaired driving and on heavy use among adults. Normalization, as we see it, means treating those questions with the same data and the same seriousness applied to any other legal product.
Sources: State Law Tracker · Colorado Department of Revenue: Marijuana tax data · JAMA Pediatrics (2024): adolescent use after legalization
March 6, 2026 · Updated October 25, 2026
The Controlled Substances Act of 1970 placed marijuana in Schedule I, the category for drugs with a high potential for abuse and no accepted medical use. Congress made that placement while a national commission studied the drug. In 1972 the commission recommended ending criminal penalties for possession for personal use. The recommendation was not adopted.
Enforcement grew in the decades that followed. The Drug Enforcement Administration was created in 1973, and marijuana possession became one of the most common reasons for arrest in the United States. An ACLU analysis of 2018 data found that Black Americans were 3.64 times more likely than white Americans to be arrested for marijuana possession, despite similar rates of use.
The policy's origins remain debated. A quote attributed to John Ehrlichman, a Nixon domestic policy adviser, describing drug enforcement as a political tool was published by Harper's in 2016, from a 1994 interview; Ehrlichman's family has disputed it. The documented record, including the commission report and the arrest data, stands on its own.
The classification is now being revisited. In 2023, federal health officials recommended moving marijuana to Schedule III, and in April 2026 the Justice Department ordered state-licensed medical marijuana moved to that schedule. The order is being challenged in court, and the outcome will decide how federal law treats the medical programs most states already run.
Sources: ACLU: A Tale of Two Countries (2020) · Harper's: Legalize It All (2016) · Federal Register: April 28, 2026 rescheduling order
March 7, 2026 · Updated October 25, 2026
Alcohol and cannabis are often debated as if their risks were similar. The federal numbers show they are not.
The CDC attributes more than 178,000 U.S. deaths a year to excessive alcohol use, from liver disease, poisoning, crashes, violence and cancer, including thousands of deaths among people under 21. Severe alcohol withdrawal can be life-threatening and may require hospital care.
Cannabis carries a different risk profile. Fatal overdose from cannabis alone is considered unlikely, and withdrawal can bring irritability, anxiety, trouble sleeping, reduced appetite, headaches and stomach pain. Its documented harms are real but of a different kind: impaired driving, cannabis use disorder, severe vomiting syndrome in some heavy users, and accidental ingestion by children.
Youth protection is the most common reason given for cannabis restrictions, and it is a legitimate one. The same standard, applied consistently, would also weigh the harm alcohol does to young people every year.
The comparison is not an argument that cannabis is harmless. It is an argument for proportion: rules for each substance should follow its measured risks.
Sources: CDC: Deaths from excessive alcohol use · CDC: Cannabis FAQ · MedlinePlus: Alcohol withdrawal · NIDA: Cannabis (marijuana)